Cell Technology, Inc. Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for Glioblastoma
Published: Nov 01, 2011
NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for rindopepimut for the treatment of Glioblastoma (GB). GB is the most common and aggressive form of brain cancer. Rindopepimut is an immunotherapy that targets the tumor-specific oncogene (a growth promoter), EGFRvIII.